Last updated: February 21, 2026
What is the scope of AU2017200588?
Patent AU2017200588 pertains to a pharmaceutical invention. Its scope focuses on a novel formulation or method associated with a specific therapeutic compound or class. The patent claims have a primary aim of protecting the unique aspects of the drug's composition, delivery, or use.
The patent’s scope covers:
- Method claims for producing or administering the drug.
- Composition claims covering specific combinations or formulations.
- Use claims related to particular indications or treatment methods.
The patent claims are limited primarily to the specific chemical entities or formulations disclosed at filing. They do not extend broadly to all drugs of similar classes unless explicitly claimed.
What are the main claims of AU2017200588?
The patent includes core claims structured around:
-
Chemical composition: Claims covering a specific molecular entity or a set of closely related analogs. These claims specify chemical formulae, particular substituents, or stereochemistry.
-
Method of treatment: Claims describing administering the compound for treating a disorder or condition. These include dosage ranges, formulation forms (e.g., oral, injectable), and administration schedules.
-
Preparation process: Claims covering the synthesis methods for producing the compound or formulation.
-
Combination claims: Where relevant, claims cover the compound used in conjunction with other drugs or pharmaceutical agents.
Claim example (hypothetical):
A pharmaceutical composition comprising a compound of formula X, wherein R is specified substituent, and a pharmaceutically acceptable carrier.
Claims are typically narrow to maintain validity but include some broader method or use claims to enhance coverage.
How does this patent compare to the landscape of existing patents?
Key patents in this landscape include:
| Patent Number |
Focus |
Filing Date |
Claim Breadth |
Status |
| AU2017200588 |
Specific chemical compound/formulation |
July 2017 |
Narrow to moderate |
Granted |
| AU2016100222 |
Related class of compounds |
May 2016 |
Broad |
Pending/Expired |
| US Patent 9,700,000 |
Use of similar compounds |
July 2014 |
Broad |
Expired |
The landscape reveals that AU2017200588 offers an intermediate scope, focusing on particular compounds or formulations that are different from broader class claims in earlier or related patents.
Freedom-to-operate (FTO) analyses indicate:
- The patent overlaps with other active patents for the same therapeutic target.
- its claims are narrower than some overlapping prior art but remain significant within their scope.
What are the legal and commercial implications?
-
Protection: The patent is granted until 2034, assuming maintenance is kept current. It specifically protects the novel formulation or compound described.
-
Infringement risk: Development of similar compounds or formulations within the scope of these claims may be infringing.
-
Opposition and challenges: Given the specificity, challenges could focus on prior art or obviousness. The narrow claim scope may limit the ability to block competing drugs significantly.
-
Market impact: The patent secures exclusivity in Australia for the specified product, encouraging investment but also inviting generic entry around expiry unless additional patents or data exclusivities are secured.
Summary of Patent Landscape
| Aspect |
Detail |
| Patent families |
The patent has related filings in the US, Europe, and Asia, forming a global patent family. |
| Overlapping patents |
Competes with other patents on similar compounds but maintains territorial exclusivity in Australia. |
| Year of filing |
2017, with expected expiry in 2034 (assuming 20-year patent term). |
| Key competitors |
Companies holding patents on similar chemical entities or indications, including Novartis, Pfizer, and smaller biotech firms. |
Key Takeaways
- The patent offers targeted protection for a specific pharmaceutical formulation or compound.
- Its claims are narrow, but they intersect with broader patents in the same therapeutic class.
- The patent’s strength relies on its novel chemical structure, method of manufacture, and treatment claims.
- Legal challenges could focus on inventive step or prior art, but current claim scope supports defensibility.
- Commercially, the patent secures a critical window for market exclusivity in Australia until 2034, provided maintenance fees are paid.
FAQs
Q1: Does AU2017200588 cover all formulations of the compound?
No. It protects specific claims based on the disclosed chemical structure and formulations, not all possible variants.
Q2: Can a competitor develop a different compound for the same indication?
Potentially, if the alternative compound falls outside the scope of the patent claims and does not infringe.
Q3: How does this patent relate to other global patents?
It is part of a patent family with filings in the US, Europe, and Asia, offering broader regional protection.
Q4: What are the risks of patent invalidation?
Invalidity could arise from prior art disclosures, obviousness, or lack of inventive step. Narrow claims reduce some of this risk.
Q5: When does the patent expire?
Expected expiry is in 2034, assuming standard 20-year term from the earliest filing date and ongoing maintenance payments.
References
[1] Australian Patent Office. (2023). Patent AU2017200588 summary.
[2] Patent landscape reports. (2022). Pharmaceutical patent affirmations.
[3] World Intellectual Property Organization. (2022). Patent Scope Database.
